John Valliant, PhD
Chief Executive Officer
Vice President Quality
Senior Director, Finance & Administration
Senior Director, Business Development
Director, Manufacturing Operations
Director, Radiopharmaceutical Development and Supply
Chief Regulatory Officer
Director, Human Resources
Dr. John Valliant is the founder of CPDC. Dr. Valliant oversees the strategic directions of the scientific and commercial programs of the CPDC, to ensure the Centre’s long-term vision and sustainability.
John is currently Professor in the Department of Chemistry and Chemical Biology, at McMaster University. He is recognized internationally for his work in radiopharmaceutical chemistry. His current research focuses on developing novel radiolabeling methods and compound discovery strategies, in order to create clinically relevant imaging and therapeutic drug candidates. Thus far, John has published more than 100 peer review research papers and holds 16 patents in the area of radiochemistry and radiopharmaceuticals. He completed his PhD at McMaster University, followed by a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT).
John was selected as one of ‘Canada’s Top 40 Under 40’ in 2009, a distinction that recognized his exceptional work to advance radiopharmaceutical technology and education, improve patient care, and generate economic growth, through his work at the CPDC and McMaster University. More recently he was a co-recipient of the Brockhouse Prize for Interdisciplinary Research in Science and Engineering (2015).
Justyna Kelly joined the Centre for Probe Development and Commercialization (CPDC) in 2010, founding CPDC’s Microbiology and Sterility Assurance programs. Since that time, she has held roles of increasing responsibility in manufacturing operations and product development. Working closely with teams across the Company, Justyna successfully led key internal and client manufacturing programs and launched a number of therapeutic products for clinical supply. Shifting from manufacturing programs, Justyna led CPDC’s development programs, including new initiatives and collaborations in the field of medical isotopes. In 2019, she was appointed as CPDC’s Interim Chief Executive Officer. Justyna has a MSc. degree in biochemistry from McMaster University.
Fina Puig oversees quality operations to support CPDC’s GMP compliance across the company in support of clinical and commercial products. Fina is responsible for Quality Control, Quality Assurance and Microbiology and Sterility Assurance. She has led the Centre successfully through Health Canada and FDA audits.
Fina has over 25 years of pharmaceutical industry experience with a successful track record of regulatory inspections (FDA, EMA, Anvisa, PMDA). Prior to CPDC Fina was Head of Pharmaceutical Quality Systems in Boehringer Ingelheim (Germany) and before she was Executive Director Quality and Environment, Health and Safety (EHS) in Boehringer Ingelheim Inc. Petersburg, VA (USA).
Fina holds a Bachelor and Master’s Degree in Pharmaceutical Science from the University of Barcelona (Spain) and a Master of Business Administration (Directors Development Program, ESADE Business School – Barcelona, Spain).
Angela Lauretani joined CPDC in July 2015 as the Finance Controller and transitioned into her current role as Senior Director, Finance and Administration in February 2018. In her current role, Ms. Lauretani is responsible for the Finance operations of CPDC, including grant reporting, budgeting and commercialization efforts. She also oversees the IT and Administration departments.
Angela has over 15 years of experience in financial management, previously employed by a publicly traded company (NYSE) for 10 years and began her professional career in public accounting with KPMG, where she obtained her Chartered Accountant, CPA designation. Angela holds an Honours Bachelor of Commerce from McMaster University.
Bruno Paquin joined CPDC in November 2018 as the Director, Business Development and since December 2019, is now Senior Director, Business Development. In his current role, Bruno oversees all the business development activities including management of the service contracts, collaboration and licensing agreements.
Bruno received his PhD in Biochemistry from Université de Montréal before conducting his post-doctoral research at the University at Albany, NY. He became the Laboratory Director at Université de Montréal, Département de Biochimie, where he was responsible for the management and direction of a team of scientists. In 2000, he became the head of the Technology Development Unit at Genizon Biosciences Inc., where he transitioned to business development and was appointed the Executive Director, Head of Business Development. Bruno then went on to become VP of Business Development for Immuni T in Montréal in 2011 until he joined CPDC.
Constantinos Economou joined CPDC in June 2010 as a Cyclotron Engineer and transitioned into his current role as Director, Manufacturing Operations in September 2017. In his role, Mr. Economou is responsible for the Manufacturing Operations across the CPDC network.
Constantinos has over 20 years of experience in manufacturing. Prior to joining CPDC in 2010, Constantinos spent 11 years in the automotive sector in various Engineering roles. Constantinos is a Professional Engineer and holds a Bachelor’s Honours Degree in Mechanical Engineering as well as a Master’s of Science in Advanced Manufacturing from the University of Salford, Manchester, UK.
Valerie Hergott joined CPDC in June 2009 as the Centre’s first production technologist. Since that time Valerie has held roles of increasing responsibility in both process development and project management. Valerie has led a number of successful tech transfer programs which have translated into clinical supply and is currently the Director of Radiopharmaceutical Development and Supply. In her role, Ms. Hergott is responsible for the contract manufacturing development programs and supply of clinical products at the Hamilton location.
Valerie has over 15 years of experience in the radiopharmaceutical manufacturing space, previously employed at Lantheus Medical Imaging. Valerie holds a Project Management Professional (PMP) certification from the Project Management Institute. She graduated in 2004 from Brock University with a Bachelor’s Honours Degree in Biotechnology.
Anne Goodbody joined the CPDC in 2008 and oversees CPDC’s regulatory functions, clinical operations and translational research. At CPDC she has successfully led the development of radiopharmaceuticals, covering early stage development through to market authorization.
Anne has over 25 years of pharmaceutical research and development experience. Prior to joining the CPDC, she was the VP Drug Development at Vasogen Inc., where she managed the company’s drug development program. In previous positions as VP of Development at Molecular Insight Pharmaceuticals and Director of Development at Resolution Pharmaceuticals, she ran successful radiopharmaceutical development programs. She has also worked in research and development at Allelix Inc. and Bayer.
Anne holds a PhD in biochemistry from the University of Cambridge (UK), has published extensively and is a named inventor on 15 issued patents.
Anton Knezovic joined CPDC in 2018 as Director Human Resources and has responsibility as the Delivery Team Lead for a new facility spin off. In his role, Mr. Knezovic is responsible for strategic implementation and execution of all Human Resources’ objectives to assure organizational success across the CPDC network.
Mr. Knezovic has over 12 years of experience in the human resources profession. Prior to joining CPDC in 2018, Mr. Knezovic spent a vast majority of his career in the manufacturing and pharmaceutical industries focusing on organizational development, employee and labour relations, talent acquisition and full cycle talent management. Mr. Knezovic holds a Bachelor’s Degree in Science, Biology as well as a post graduate Diploma in Human Resource Management.
CPDC is governed by an independent Board of Directors. Board members represent all key sectors associated with the CPDC. The Board of Directors works with the CEO and CPDC executive team to shape the CPDC’s future direction and success.
John ThornbackChair of the CPDC Board of Directors
Gay YuyitungVice-Chair of the CPDC Board of Directors
Mark LundieDirector, Medical Affairs, Rare Diseases Pfizer Canada Inc.
Karen GulenchynNuclear Medicine Physician, Hamilton Hospitals and Cambridge Memorial Hospital
Justyna KellyCEO, CPDC
John ValliantFounder, CPDC Principal Investigator
Stewart FastSenior Program Manager, Networks of Centres of Excellence
Damian LambManaging Director, Genesys Capital
Jean-Claude ProvostManaging Partner at Theranostics Consulting
Paul SchafferAssociate Laboratory Director, Life Science TRIUMF
Robert SutherlandDirector, CPDC
Annick Van den AbbeelePresident-Elect, International Cancer Imaging Society
VANCOUVER, Canada and NEW YORK, United States, May 20, 2020 – ARTMS Inc. a global leader in developing technology that transforms the production of the world’s most-used diagnostic imaging isotopes, today announced that it has raised US$19 million in a Series A financing. The investment was led by New York based Deerfield Management Company with
CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.
CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.
CPDC’s manufacturing facilities are approved by Health Canada for the production of positron emitting radiopharmaceuticals.
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.
CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.
CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.
Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.
Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.
Molecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.